Related Experiment Video

Updated: Oct 1, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Thymidine kinase in epithelial ovarian cancer: relationship with the other pyrimidine pathway enzymes

Ritsuto Fujiwaki1, Kohkichi Hata, Kentaro Nakayama

  • 1Department of Obstetrics and Gynecology, Shimane Medical University, Izumo, Japan. fuji39@shimane-med.ac.jp

International Journal of Cancer
|May 7, 2002
PubMed

Insights

Thymidine kinase 1 (TK1) is elevated in epithelial ovarian cancer, correlating with poorer survival. Targeting TK1, along with other pyrimidine enzymes, may offer new therapeutic strategies for ovarian cancer.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Thymidine kinase 1 (TK1) is a key enzyme in pyrimidine salvage DNA synthesis.
  • The specific roles of TK1 in epithelial ovarian cancer and its relationship with other pyrimidine pathway enzymes are not fully understood.

Purpose of the Study:

  • To investigate the role of TK1 gene expression and activity in epithelial ovarian cancer.
  • To explore the correlations between TK1 and other pyrimidine pathway enzymes (TS, TP, DPD) in ovarian tumors.
  • To assess the prognostic significance of TK1 in epithelial ovarian cancer patients.

Main Methods:

  • Quantitative analysis of TK1, TS, TP, and DPD gene expression using RT-PCR in 69 epithelial ovarian cancer samples, 8 low-malignant-potential tumors, 16 benign ovarian tumors, and 34 normal ovaries.
  • Measurement of cytosolic and serum TK activities via radioenzymatic assay.
  • Statistical analysis to correlate gene expression, enzyme activity, and patient survival.

Main Results:

  • TK1 gene expression and its ratios with TS, TP, and DPD were significantly higher in epithelial ovarian cancer compared to normal ovaries.
  • TK1 gene expression positively correlated with cytosolic/serum TK activity, TS and TP gene expression, and the TP/DPD ratio in ovarian cancer.
  • Elevated TK1 gene expression was associated with significantly poorer patient survival.
  • Combined high expression of TK1, TS, and TP further increased the risk of cancer death.

Conclusions:

  • TK1, along with TS, TP, and DPD, plays a significant role in the malignant behavior of epithelial ovarian cancer.
  • TK1 gene expression and activity are potential biomarkers for prognosis in ovarian cancer.
  • Combination therapies targeting TK1 and other pyrimidine pathway enzymes represent a promising therapeutic avenue for epithelial ovarian cancer.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...